Peter Mullen

PARP cleavage as a means of assessing apoptosis.

Flow cytometric DNA analysis of human cancer cell lines.

The use of Matrigel to facilitate the establishment of human cancer cell lines as xenografts.

Antisense oligonucleotide targeting of Raf-1: importance of raf-1 mRNA expression levels and raf-1-dependent signaling in determining growth response in ovarian cancer.

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.

Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.

Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells.

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling.

Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo.

Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.

Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.

Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy.

Serotonin, a catecholamine?

Pertuzumab for the treatment of ovarian cancer.

Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.

Phosphoprotein pathway profiling of ovarian carcinoma for the identification of potential new targets for therapy.

Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.

Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt.

Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy.

Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.

Model-based global sensitivity analysis as applied to identification of anti-cancer drug targets and biomarkers of drug resistance in the ErbB2/3 network.

Diversity of matriptase expression level and function in breast cancer.

Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines.

Effect of short- and long-term treatment with valproate on carnitine homeostasis in humans.

New strategies for targeting the hypoxic tumour microenvironment in breast cancer.